We are live on ! Find out more
AYTU icon

AYTU BioPharma
AYTU

10 hedge funds and large institutions have $839K invested in AYTU BioPharma in 2018 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,532% more capital inflows, than outflows

Capital inflows: $1.06M | Capital outflows: $65.2K

52.37% more ownership

Funds ownership: 6.58% → 58.94% (+52%)

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

25% more funds holding

Funds holding: 8 → 10 (+2)

Holders
10
Holders Change
+2
Holders Change %
+25%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
3
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$528K
2
Armistice Capital
Armistice Capital
New York
+$110K
3
Wexford Capital
Wexford Capital
Florida
+$98.7K
4
Renaissance Technologies
Renaissance Technologies
New York
+$86.6K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$74.4K

Top Sellers

Rank Fund Capital Flow
1
Alambic Investment Management
Alambic Investment Management
California
-$36K
2
UBS Group
UBS Group
Switzerland
-$23K
3
NEA Management Company
NEA Management Company
Maryland
-$6K
4
Bank of America
Bank of America
North Carolina
-$220

AYTU Hedge Fund Activity: Q4 2018 in Review

10 of the 4,506 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q4 2018, worth a combined $839K — up 158% from $325K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new AYTU positions and 4 closed out — a net gain of 2 holders — while 3 added to existing stakes and 0 trimmed.

The largest buyer was Sabby Management, adding an estimated $528K. The largest seller was Alambic Investment Management, exiting entirely with an estimated $36K sold.

  • 10 institutional investors held AYTU BioPharma (AYTU) as of Q4 2018, up from 8 in Q3 2018.
  • Funds reported $839K of AYTU BioPharma stock for Q4 2018, up 158% quarter-over-quarter.
  • 6 funds opened new AYTU BioPharma positions in Q4 2018 and 4 closed out, a net change of +2 holders.
  • The largest AYTU BioPharma buyer in Q4 2018 was Sabby Management, an estimated $528K added.
  • The largest AYTU BioPharma seller in Q4 2018 was Alambic Investment Management, an estimated $36K sold.

Based on aggregated 13F filings for Q4 2018.